Epithelial ovarian cancer is the most common and deadliest form of ovarian cancer, often diagnosed late because it progresses with few or no symptoms. Although platinum-based chemotherapy remains the standard first-line treatment, advances in our understanding of tumour biology have led to new therapies that target specific molecular pathways. This thesis explores the range of pharmacological treatments currently used in managing epithelial ovarian cancer, including chemotherapy, targeted agents, hormonal therapies, and newer drugs still in development. It also looks at how these treatments work, why some patients develop resistance, and the possible side effects that may occur. In addition, the role of palliative care is discussed as a key part of supporting patients, especially in advanced stages. By reviewing both established treatments and emerging options, this work highlights how the approach to ovarian cancer is becoming more personalised and focused on improving both survival and quality of life.